The natural tension between the executive and legislative branches of government is naturally affected by the results of elections, and the unseating of the Democratic majority in the U.S. Senate in the Nov. 4 elections draws a bright line between Capitol Hill and the Obama administration. John Manthei of Latham & Watkins (Washington) said in a Nov. 5 briefing that the 114th Congress is likely to be unusually busy with FDA-related legislation, but he added, "in light of the election yesterday . . . I think FDA should fully expect to be in the crosshairs of the Hill."